184 related articles for article (PubMed ID: 34307143)
1. Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma.
Fisch D; Bozorgmehr F; Kazdal D; Kuon J; Klotz LV; Shah R; Eichhorn F; Kriegsmann M; Schneider MA; Muley T; Stenzinger A; Bischoff H; Christopoulos P
Front Oncol; 2021; 11():673901. PubMed ID: 34307143
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
5. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience.
Sarkaria IS; Iyoda A; Roh MS; Sica G; Kuk D; Sima CS; Pietanza MC; Park BJ; Travis WD; Rusch VW
Ann Thorac Surg; 2011 Oct; 92(4):1180-6; discussion 1186-7. PubMed ID: 21867986
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer.
Spence MM; Hui RL; Chang JT; Schottinger JE; Millares M; Rashid N
J Manag Care Spec Pharm; 2017 Feb; 23(2):195-205. PubMed ID: 28125366
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
9. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
[TBL] [Abstract][Full Text] [Related]
10. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.
Lowczak A; Kolasinska-Cwikla A; Osowiecka K; Glinka L; Palucki J; Rzepko R; Doboszynska A; Cwikla JB
Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33525370
[No Abstract] [Full Text] [Related]
12. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features and Outcomes Analysis of Surgical Resected Pulmonary Large-Cell Neuroendocrine Carcinoma With Adjuvant Chemotherapy.
Shen Y; Hu F; Li C; Xu J; Zhong R; Zhang X; Chu T; Han B
Front Oncol; 2020; 10():556194. PubMed ID: 33335851
[TBL] [Abstract][Full Text] [Related]
14. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
[TBL] [Abstract][Full Text] [Related]
17. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract][Full Text] [Related]
20. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.
Alese OB; Jiang R; Shaib W; Wu C; Akce M; Behera M; El-Rayes BF
Oncologist; 2019 Jul; 24(7):911-920. PubMed ID: 30482824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
